ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SPRB Spruce Biosciences Inc

0.8022
0.0622 (8.41%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,417,986
Bid Price 0.80
Ask Price 0.8022
News -
Day High 0.80

Low
0.6786

52 Week Range

High
5.95

Day Low 0.73
Company Name Stock Ticker Symbol Market Type
Spruce Biosciences Inc SPRB NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0622 8.41% 0.8022 19:59:40
Open Price Low Price High Price Close Price Prev Close
0.73 0.73 0.80 0.7859 0.74
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,886 1,417,986 $ 0.7726491 $ 1,095,606 - 0.6786 - 5.95
Last Trade Time Type Quantity Stock Price Currency
19:59:40 formt 125 $ 0.8022 USD

Spruce Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
32.16M 40.71M - 0 -46.18M -1.13 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Spruce Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No SPRB Message Board. Create One! See More Posts on SPRB Message Board See More Message Board Posts

Historical SPRB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.740.800.67860.72825212,147,3640.06228.41%
1 Month5.375.950.67861.312,952,921-4.57-85.06%
3 Months2.705.950.67861.811,246,987-1.90-70.29%
6 Months2.235.950.67861.80664,599-1.43-64.03%
1 Year2.275.950.67861.88388,587-1.47-64.66%
3 Years15.9617.990.67863.50628,234-15.16-94.97%
5 Years17.0035.600.67863.84555,510-16.20-95.28%

Spruce Biosciences Description

Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).

Your Recent History

Delayed Upgrade Clock